ເລນວາທິນິບ (ເລນວິມາ)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of thyroid cancer.
Eisai ກ່າວວ່າ Lenvima ຈະກາຍເປັນມາດຕະຖານໃຫມ່ສໍາລັບການປິ່ນປົວທາງດ້ານຄລີນິກຂອງມະເຮັງ thyroid ທີ່ບໍ່ສາມາດແກ້ໄຂໄດ້. ອຸດສາຫະກໍາແມ່ນ optimistic ຫຼາຍກ່ຽວກັບ Lenvima, ແລະມັນຄາດວ່າຢາດັ່ງກ່າວຈະກາຍເປັນງົວເງິນສົດໃຫມ່ສໍາລັບ Eisai, ຍອດຂາຍປະຈໍາປີຢູ່ທີ່ຫຼາຍກວ່າ $ 1 ຕື້.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved tumor volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
ໃນປັດຈຸບັນ, ເຖິງແມ່ນວ່າມະເຮັງຕ່ອມ thyroid ສ່ວນໃຫຍ່ສາມາດປິ່ນປົວໄດ້, ມີທາງເລືອກໃນການປິ່ນປົວຫນ້ອຍຫນຶ່ງເມື່ອມັນຮ້າຍແຮງຂຶ້ນ. ມະເຮັງຕ່ອມ thyroid ທີ່ແຕກຕ່າງກັນ (DTC) ແມ່ນເນື້ອງອກ thyroid malignant ທົ່ວໄປທີ່ສຸດ, ແລະເຫດການຂອງມັນໄດ້ເພີ່ມຂຶ້ນຢ່າງຕໍ່ເນື່ອງໃນຊຸມປີມໍ່ໆມານີ້.
Lenvatinib ແມ່ນຢາຍັບຍັ້ງ tyrosine kinase (RTK) ຫຼາຍຕົວຮັບທາງປາກທີ່ມີຮູບແບບການຜູກມັດແບບໃຫມ່. ນອກເຫນືອຈາກການຍັບຍັ້ງ RTKs ອື່ນໆທີ່ກ່ຽວຂ້ອງກັບການຂະຫຍາຍເນື້ອງອກແລະເສັ້ນທາງສັນຍານ oncogenic, ມັນຍັງສາມາດຍັບຍັ້ງກິດຈະກໍາການຂະຫຍາຍຕົວຂອງ endothelial vascular (VEGF) ກິດຈະກໍາ kinase receptor.
